What is AngioScore?
Headquartered in Fremont, California, AngioScore is a privately held endovascular company dedicated to the development of novel angioplasty catheters. The company's flagship innovation, the AngioSculpt Scoring Balloon Catheter, represents a significant advancement in interventional cardiology. By integrating nitinol-scoring elements with traditional balloon catheter architecture, the device provides focal concentrations of dilating force. This unique mechanism effectively minimizes balloon slippage, commonly referred to as geographic miss, and facilitates superior luminal expansion in stenotic arteries. Through this specialized approach, AngioScore addresses a critical need for precision in treating complex vascular conditions, establishing itself as a key player in the medical device industry.
How much funding has AngioScore raised?
AngioScore has raised a total of $12M across 1 funding round:
Private Equity
$12M
Private Equity (2012): $12M with participation from Saints capital, Telegraph Hill Partners, QuestMark Partners, California Technology Ventures, LLC, and Pelion Venture Partners
Key Investors in AngioScore
Saints Capital
Saints Capital is a pioneering investment firm specializing in GP-led transactions within the venture secondary market, providing liquidity solutions for private companies.
QuestMark Partners
QuestMark Partners is an expansion-stage investment firm that focuses on partnering with exceptional management teams to build market-leading companies in sectors such as healthcare IT.
California Technology Ventures, LLC
California Technology Ventures specializes in direct investments in technology and life science companies, focusing on building world-class enterprises through strategic guidance.
What's next for AngioScore?
With the successful closure of this major strategic investment, AngioScore is poised to enter a new phase of commercial scaling and product development. The company's focus will likely shift toward broadening the clinical adoption of the AngioSculpt platform and potentially exploring further iterations of its scoring technology. Given the enterprise-level nature of the funding, the firm is expected to prioritize operational efficiency and market penetration, ensuring that its endovascular solutions remain at the forefront of clinical practice. As the company navigates this growth trajectory, the strategic guidance provided by its institutional partners will be instrumental in navigating the complexities of the global healthcare market and maintaining its competitive edge in the treatment of arterial disease.
See full AngioScore company page
